{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:07:14Z","timestamp":1779944834396,"version":"3.53.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) play a regulatory roles in metabolism across several tissues and have potential value in the treatment of MASLD. A novel umbrella review was conducted to assess the efficacy and safety of GLP-1 RAs in MASLD in multiple dimensions. Following the PRISMA 2020 guidance, five databases were searched from inception to 30 September, 2025. The quality of the included systematic reviews was assessed using AMSTAR 2. Twenty-three meta-analyses and systematic reviews were included. All outcomes regarding the efficacy of GLP-1 RAs in MASLD were summarized into five categories: liver characteristics, liver enzyme levels, anthropometric measurements, metabolic markers, and inflammatory markers. GLP-1 RAs show potential benefits in improving MASLD across multiple dimensions with a relatively acceptable safety profile, but nearly 80% of included reviews are of critically low quality with high evidence overlap. Thus, our findings are preliminary and hypothesis-generating. High-quality studies are urgently needed.<\/jats:p>","DOI":"10.3389\/fmed.2026.1783429","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:58:34Z","timestamp":1779944314000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review"],"prefix":"10.3389","volume":"13","author":[{"given":"Hui","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Taizhou Hospital, Zhejiang University, Linhai","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Heng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Taizhou Hospital, Zhejiang University, Linhai","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ni","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Hsin","family":"Tung","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Sheng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Taizhou Hospital, Zhejiang University, Linhai","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s42255-024-00985-1","article-title":"From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research","volume":"6","author":"Hsu","year":"2024","journal-title":"Nat Metab Apr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.4254\/wjh.v15.i11.1210","article-title":"Global burden of cirrhosis and other chronic liver diseases due to nonalcoholic fatty liver disease, 1990-2019","volume":"15","author":"Liu","year":"2023","journal-title":"World J Hepatol Nov 27."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci Jan."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d","volume":"24","author":"Fang","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1007\/s00125-025-06527-y","article-title":"Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence","volume":"68","author":"Arredouani","year":"2025","journal-title":"Diabetologia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"970292","DOI":"10.3389\/fphys.2022.970292","article-title":"The AMPK pathway in fatty liver disease","volume":"13","author":"Fang","year":"2022","journal-title":"Front Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"622589","DOI":"10.3389\/fendo.2020.622589","article-title":"Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1507\/endocrj.EJ24-0168","article-title":"Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"71","author":"Xu","year":"2024","journal-title":"Article Endocrine Journal."},{"key":"B14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5114\/pg.2022.112775","article-title":"The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials","volume":"18","author":"Malik","year":"2023","journal-title":"Prz Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8936865","DOI":"10.1155\/2021\/8936865","article-title":"GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"2021","author":"Rezaei","year":"2021","journal-title":"Canad J Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e71366","DOI":"10.7759\/cureus.71366","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Njei","year":"2024","journal-title":"Cureus."},{"key":"B17","doi-asserted-by":"publisher","first-page":"101568","DOI":"10.1016\/j.clinre.2020.10.012","article-title":"Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Short Survey","volume":"45","author":"Kalogirou","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10654-019-00505-6","article-title":"Umbrella reviews: what they are and why we need them","volume":"34","author":"Papatheodorou","year":"2019","journal-title":"Eur J Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-0716-1566-9_8","article-title":"Umbrella reviews: what they are and why we need them","volume":"2345","author":"Papatheodorou","year":"2022","journal-title":"Methods Mol Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1605526","DOI":"10.3389\/ijph.2023.1605526","article-title":"Effectiveness and safety of COVID-19 vaccinations: an umbrella meta-analysis","volume":"68","author":"Jiesisibieke","year":"2023","journal-title":"Int J Public Health."},{"key":"B21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj."},{"key":"B22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","article-title":"Systematic review finds overlapping reviews were not mentioned in every other overview","volume":"67","author":"Pieper","year":"2014","journal-title":"J Clin Epidemiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"118080","DOI":"10.1016\/j.ecoenv.2025.118080","article-title":"The association between air pollution and three types of diabetes: an umbrella review of systematic reviews and meta-analyses","volume":"294","author":"Jiang","year":"2025","journal-title":"Ecotoxicol Environ Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"m3502","DOI":"10.1136\/bmj.m3502","article-title":"Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review","volume":"371","author":"Okoth","year":"2020","journal-title":"Bmj."},{"key":"B25","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Bmj."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0194127","DOI":"10.1371\/journal.pone.0194127","article-title":"Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses","volume":"13","author":"Bellou","year":"2018","journal-title":"PLoS ONE."},{"key":"B27","doi-asserted-by":"publisher","first-page":"790901","DOI":"10.3389\/fphar.2021.790901","article-title":"Safety of cinnamon: an umbrella review of meta-analyses and systematic reviews of randomized clinical trials","volume":"12","author":"Gu","year":"2021","journal-title":"Front Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"102539","DOI":"10.1016\/j.dsx.2022.102539","article-title":"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis","volume":"16","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e32892","DOI":"10.1097\/MD.0000000000032892","article-title":"Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a systematic review and meta-analysis of 16 RCTs","volume":"102","author":"Zhao","year":"2023","journal-title":"Medicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.17235\/reed.2020.6392\/2019","article-title":"The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"112","author":"Fan","year":"2020","journal-title":"Rev Esp Enferm Dig."},{"key":"B32","first-page":"500","article-title":"A meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"52","author":"Tang","year":"2017","journal-title":"Chin Pharm J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.3748\/wjg.v29.i37.5327","article-title":"Efficacy and safety of semaglutide in non-alcoholic fatty liver disease","volume":"29","author":"Zhu","year":"2023","journal-title":"World J Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1509947","DOI":"10.3389\/fmed.2025.1509947","article-title":"Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"12","author":"Huang","year":"2025","journal-title":"Front Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"694284","DOI":"10.3389\/fendo.2021.694284","article-title":"What is an L-Cell and how do we study the secretory mechanisms of the L-Cell?","volume":"12","author":"Kuhre","year":"2021","journal-title":"Front Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice","volume":"154","author":"Panjwani","year":"2013","journal-title":"Endocrinology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3748\/wjg.v30.i23.2964","article-title":"Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease","volume":"30","author":"Rocho\u0144","year":"2024","journal-title":"World J Gastroenterol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/db24-0861","article-title":"The GLP-1 receptor agonist dulaglutide attenuates hepatic steatosis in obesity via a weight-independent mechanism","volume":"74","author":"Shantaram","year":"2025","journal-title":"Diabetes."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1161\/ATVBAHA.117.310251","article-title":"GLP-1 elicits an intrinsic gut-liver metabolic signal to ameliorate diet-induced VLDL overproduction and insulin resistance","volume":"37","author":"Khound","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/hep.31229","article-title":"Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology","volume":"72","author":"Sookoian","year":"2020","journal-title":"Hepatology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/1873-3468.13879","article-title":"SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production","volume":"594","author":"Lin","year":"2020","journal-title":"FEBS Lett."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/biom10091256","article-title":"Impact of conventional and atypical MAPKs on the development of metabolic diseases","volume":"10","author":"Kassouf","year":"2020","journal-title":"Biomolecules"},{"key":"B51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jcag\/gwae057","article-title":"Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"8","author":"Potter","year":"2025","journal-title":"J Can Assoc Gastroenterol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","article-title":"Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"18","author":"Fang","year":"2024","journal-title":"Prim Care Diabetes."},{"key":"B53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/dom.14565","article-title":"Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"24","author":"Borodavkin","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s13300-021-01072-4","article-title":"Effects of liraglutide on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Diabetes Therapy."},{"key":"B55","doi-asserted-by":"publisher","first-page":"769069","DOI":"10.3389\/fendo.2021.769069","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Endocrinol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/MCG.0000000000001556","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: a systematic review and meta-analysis","volume":"55","author":"Jianping","year":"2021","journal-title":"J Clin Gastroenterol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"609110","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"B59","doi-asserted-by":"publisher","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","article-title":"A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal","year":"2021","journal-title":"Sci Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.37349\/emed.2020.00008","article-title":"GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis","volume":"1","author":"Mantovani","year":"2020","journal-title":"Explor Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/HMER.S265631","article-title":"Efficacy of glucagon-like peptide-1 analogs in nonalcoholic fatty liver disease: a systematic review","volume":"12","author":"Teshome","year":"2020","journal-title":"Hepat Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"173823","DOI":"10.1016\/j.ejphar.2020.173823","article-title":"The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"893","author":"Nowrouzi-Sohrabi","year":"2021","journal-title":"Eur J Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e00163","DOI":"10.1002\/edm2.163","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review","volume":"3","author":"Lv","year":"2020","journal-title":"Endocrinol Diabetes Metab."},{"key":"B64","doi-asserted-by":"publisher","first-page":"500","DOI":"10.11669\/cpj.2017.06.015","article-title":"A meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"52","author":"Tang","year":"2017","journal-title":"Chin Pharm J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clinre.2016.11.009","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Dong","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1783429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:58:44Z","timestamp":1779944324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1783429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":65,"alternative-id":["10.3389\/fmed.2026.1783429"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1783429","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1783429"}}